The Relationship of Hepatitis Antibodies and Elevated Liver Enzymes with Impaired Fasting Glucose and Undiagnosed Diabetes

References

1. ↵
   Bock G, Chittilapilly E, Basu R, et al. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increase rates of gluconeogenesis. Diabetes 2007: 7: 1703–11.

   OpenUrl
2. ↵
   Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic statohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int 2006; 26: 566–71.

   OpenUrlCrossRefPubMed
3. ↵
   Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570–6.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005; 28: 1757–62.

   OpenUrlAbstract/FREE Full Text
5. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623–32.

   OpenUrlAbstract/FREE Full Text
6. Doi Y, Kubo M, Yonemoto K, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity 2007; 15: 1841–50.

   OpenUrlCrossRefPubMed
7. Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008; 57: 387–92.

   OpenUrlCrossRefPubMedWeb of Science
8. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28: 2913–8.

   OpenUrlAbstract/FREE Full Text
9. ↵
   Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity 2006; 14 Suppl 3: 121S–7S.

   OpenUrlCrossRef
10. ↵
    World Health Organization. Report of a World Health Organization and International Diabetes Federation meeting: screening for type 2 diabetes. Geneva: World Health Organization; 2003.
11. ↵
    Centers for Disease Control and Prevention. Prevalence of diabetes and impaired fasting glucose in adults—United States, 1999–2000. MMWR Morb Mortal Wkly Rep 2003; 52: 833–7.

    OpenUrlPubMed
12. ↵
    Koopman RJ, Mainous AG III, Liszka HA, et al. Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med 2006; 4: 427–32.

    OpenUrlAbstract/FREE Full Text
13. ↵
    Glümer C, Carstensen B, Sandbæk A, Lauritzen T, Jørgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004; 27: 727–33.

    OpenUrlAbstract/FREE Full Text
14. Franciosi M, De Berardis G, Rossi MCE, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance. Diabetes Care 2005; 28: 1187–94.

    OpenUrlAbstract/FREE Full Text
15. Thomas C, Hyppönen E, Power C. Type 2 diabetes mellitus in midlife estimated from the Cambridge Risk Score and body mass index. Arch Intern Med 2006; 166: 682–8.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    American Diabetes Association. Standards of medical care in diabetes, 2007. Diabetes Care 2007; 30: S4–S41.

    OpenUrlFREE Full Text
17. ↵
    American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27: S11–S14.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Rockville (MD): Agency for Healthcare Research and Quality; 2008 June. Publication No. 08-05116-EF-2. Available from http://www.ahrq.gov/clinic/uspstf08/type2/type2rs.htm. Accessed 2 September 2008.
19. ↵
    Diabetes UK. Position Statement: early identification of people with type 2 diabetes. London: Diabetes UK; 2006.
20. ↵
    National Center for Health Statistics, Centers for Disease Control. National Health and Nutrition Examination Survey. Data Sets and Related Documentation. Available from http://www.cdc.gov/nchs/about/major/nhanes/datalink.htm. Accessed December 2007.
21. ↵
    National Institute for Alcohol Abuse and Alcoholism. Clinicians Guide 2005. Available from http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm. Accessed 12 December 2007.
22. ↵
    Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC Scientific Statement. Markers of inflammation and cardiovascular disease. Circulation 2003; 107: 499–511.

    OpenUrl
23. ↵
    Sudman S, Warnecke R, Johnson T, O'Rourke D, Davis AM. Cognitive aspects of reporting cancer prevention examination and tests. Vital Health Stat, series 6, number 7. Washington DC: National Center for Health Statistics; 1994.